Summary of included studies evaluating the prognostic value of ctDNA mutation status in HER2-targeted therapy for breast cancer.

This table summarizes the key characteristics of the 12 included studies investigating the association between ctDNA mutation status and PFS in patients receiving anti-HER2 therapies. Data include publication year, country, study type, clinical phase, treatment regimens, ctDNA mutation frequency, and HR comparing PFS between MT and WT ctDNA groups. Abbreviations: ctDNA, circulating tumor DNA; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; WT, wild type; MT, mutant type; RCT, randomized controlled trial; N/A, not available; Y, yes; N, no. *Note: Median PFS values are reported in months. Where available, HRs and 95% confidence intervals were extracted directly from the original publications. All HRs calculated with wild-type as reference; HR>1 indicates worse prognosis in mutation group. Studies varied in anti-HER2 regimens, including monoclonal antibodies, TKIs, and ADCs, as well as combination with chemotherapy or endocrine therapy.本表格汇总了纳入的12项研究的关键特征，这些研究旨在探讨接受抗HER2治疗的患者中，循环肿瘤DNA（ctDNA，circulating tumor DNA）突变状态与无进展生存期（PFS，progression-free survival）之间的关联。所纳入的数据包括发表年份、研究开展国家、研究类型、临床试验阶段、治疗方案、ctDNA突变频率，以及用于对比突变型（MT，mutant type）与野生型（WT，wild type）ctDNA组患者PFS差异的风险比（HR，hazard ratio）。 缩写说明： ctDNA（circulating tumor DNA，循环肿瘤DNA）；PFS（progression-free survival，无进展生存期）；HR（hazard ratio，风险比）；CI（confidence interval，置信区间）；WT（wild type，野生型）；MT（mutant type，突变型）；RCT（randomized controlled trial，随机对照试验）；N/A（not available，无可用数据）；Y（yes，是）；N（no，否）。 *备注：所报告的PFS中位值以月为单位。如有可用数据，风险比（HR）及95%置信区间（CI）均直接从原始文献中提取。所有HR均以野生型作为参照组；HR>1表明突变组患者预后更差。纳入研究所采用的抗HER2治疗方案存在差异，包括单克隆抗体、酪氨酸激酶抑制剂（tyrosine kinase inhibitors，TKIs）、抗体偶联药物（antibody-drug conjugates，ADCs），以及联合化疗或内分泌治疗的方案。